Actively Recruiting
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
Led by Boryung Pharmaceutical Co., Ltd · Updated on 2025-07-24
52
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.
CONDITIONS
Official Title
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged over 19 at the time of consent
- Eligible to participate based on laboratory tests including hematology, blood chemistry, serology, urine, and ECG
- Provided written informed consent after understanding the study and investigational product details
You will not qualify if you...
- Taken investigational products within 6 months prior to study start
- History of gastrointestinal surgery (except appendectomy or hernia surgery) or gastrointestinal diseases affecting drug absorption
- Pregnant, suspected pregnancy, or nursing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
H Plus Yangji Hospital
Seoul, Gwanak-gu, South Korea, 08779
Actively Recruiting
Research Team
S
Shinyoung Oh
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here